Essential Thrombocythemia (ET) Market Report 2026

The essential thrombocythemia (et) market size has grown strongly in recent years. It will grow from $0.88 billion in 2025 to $0.93 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to myeloproliferative disorder awareness, platelet disorder diagnosis, aspirin therapy usage, hematology clinic growth, chronic disease management needs.

The essential thrombocythemia (et) market size is expected to see strong growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to genetic profiling adoption, targeted therapy development, early risk stratification, personalized hematology care, improved survival outcomes. Major trends in the forecast period include growing focus on chronic blood disorders, increased use of cytoreductive therapies, expansion of genetic mutation testing, rising emphasis on long-term disease monitoring, adoption of personalized treatment strategies.

The increasing adoption of personalized medicine is expected to drive the growth of the essential thrombocythemia (ET) market going forward. Personalized medicine is a medical approach that tailors treatment and prevention strategies based on an individual’s genetic profile, lifestyle, and environmental factors. The adoption of personalized medicine is rising due to advances in genomics, biotechnology, and data analytics, which enable more precise diagnostics and targeted therapies. In essential thrombocythemia, personalized medicine allows for targeted treatments based on specific genetic mutations, improving treatment accuracy and patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the essential thrombocythemia (ET) market.

Major companies in the essential thrombocythemia (ET) market are focusing on novel therapeutics, such as Phase 3 clinical trials for bomedemstat, to enhance treatment effectiveness, improve patient outcomes, and expand therapeutic options. These late-stage trials assess the safety and efficacy of bomedemstat, an LSD1 inhibitor, for patients requiring advanced treatment solutions. For instance, in August 2024, Merck & Co. Inc., a US-based pharmaceutical company, announced the launch of Shorespan-007, a Phase 3 clinical trial evaluating bomedemstat for the treatment of essential thrombocythemia (ET) in patients who have not previously received cytoreductive therapy. Global recruitment for Shorespan-007 has begun, with patient enrollment now underway.

In January 2023, Merck & Co. Inc., a US-based pharmaceutical company, acquired Imago BioSciences Inc. for $1.35 billion. Through this acquisition, Merck aims to strengthen its hematology portfolio by incorporating Imago BioSciences’ innovative therapies for essential thrombocythemia (ET) and other blood-related disorders, enhancing its position in developing targeted treatments for patients with hematologic conditions. Imago BioSciences Inc. is a US-based company specializing in treatments for essential thrombocythemia (ET).

Major companies operating in the essential thrombocythemia (et) market are Novartis AG, Bristol Myers Squibb Company, Incyte Corporation, PharmaEssentia Corporation, Geron Corporation, CTI BioPharma Corp., Merck Sharp and Dohme (Merck & Co Inc), Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca PLC, Gilead Sciences Inc, Swedish Orphan Biovitrum AB, Ajax Therapeutics Inc, Aclaris Therapeutics Inc, Celon Pharma, Sareum Therapeutics plc, Karyopharm Therapeutics Inc, Jazz Pharmaceuticals plc, Kura Oncology Inc, Disc Medicine Inc.

North America was the largest region in the essential thrombocythemia (ET) market in 2025. The regions covered in the essential thrombocythemia (et) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the essential thrombocythemia (et) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the essential thrombocythemia market by increasing costs of imported hematology drugs, diagnostic kits, and genetic testing tools. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported therapies. These tariffs raise treatment costs by increasing expenses for long-term cytoreductive therapy and molecular diagnostics, affecting patient access. However, they promote local drug manufacturing, supporting domestic production of hematology medications and diagnostic solutions.

The essential thrombocythemia (et) market research report is one of a series of new reports that provides essential thrombocythemia (et) market statistics, including essential thrombocythemia (et) industry global market size, regional shares, competitors with a essential thrombocythemia (et) market share, detailed essential thrombocythemia (et) market segments, market trends and opportunities, and any further data you may need to thrive in the essential thrombocythemia (et) industry. This essential thrombocythemia (et) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by excessive platelet production in the bone marrow. This condition increases the risk of blood clots, bleeding complications, and progression to myelofibrosis or leukemia. Ongoing monitoring and treatment are necessary to manage symptoms and prevent complications.

The primary treatment options for essential thrombocythemia (ET) include interferon, anagrelide, hydroxyurea, and aspirin. Interferon is a group of proteins produced by the immune system that can regulate immune responses and inhibit abnormal cell proliferation. Diagnosis of ET may involve blood tests, bone marrow biopsy, gene mutation analysis, and other methods. These treatments and diagnostic approaches are utilized by various end users, including hospitals, research organizations, and specialty clinics.

The essential thrombocythemia (ET) market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and management services, and patient management services. The market value includes the value of related goods sold by the service provider or included within the service offering. The essential thrombocythemia (ET) market also includes sales of diagnostic products, therapeutic medications, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.